Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography
of the central veins of the chest, and to determine whether dose reduction can be performed
while maintaining image quality. This will be a prospective randomized study, in which
healthy volunteers will be recruited to undergo a central veins magnetic resonance angiogram
(MRA). They will receive either the FDA-approved dose or a lower dose of Ablavar.
Quantitative and qualitative analysis will be performed on the images.